Virazide is a medicine containing the active ingredient(s) ribavirin. On this page you will find out more about Virazide, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: ribavirin
Information for medicine and pack size:
Virazide 6 g powder for inhalation, 1 vial
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
Ribavirin aerosol is indicated in the treatment of carefully selected hospitalised infants and young children below 2 years of age with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Notes. 1. RSV infection should be documented by a rapid diagnostic method such as demonstration of viral antigen in respiratory tract secretions by immunofluorescence or ELISA before or during the first 24 hours of treatment. Ribavirin aerosol is indicated only for lower respiratory tract infection due to RSV. Treatment may be initiated while awaiting rapid diagnostic test results. However, treatment should not be continued without documentation of RSV infection. 2. Ribavirin aerosol treatment must be accompanied by and does not replace standard supportive respiratory and fluid management for infants and children with severe respiratory tract infection. 3. Only severe RSV lower respiratory tract infection is to be treated with ribavirin aerosol. The vast majority of infants and children with RSV infection have lower respiratory tract disease or have disease that is mild, self-limited, and does not require hospitalisation or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalisation than would be required for a full course of ribavirin aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with ribavirin aerosol should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity or cardiopulmonary disease may increase the severity of the infection and its risk to the patient. High risk infants and young children with these underlying conditions may benefit from ribavirin treatment, although efficacy has been evaluated in only a small number of such patients.
Table of characteristics
|Visual appearance||White, crystalline powder.|
|Dosage Form||Solution, powder for|
|Route of administration||Inhalation|
6g: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Store in a Dry Place|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.